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Central nervous system (CNS) relapse is not a rare presentation in acute myeloid leukemia (AML) as its
incidence ranges between 2% and 9%. It manifests with meningeal leukemia, cranial nerve palsies or
cerebral mesenchymal myeloid sarcoma. We herein report the case of a 69 year-old female that pre-
sented a pseudo-Guillain–Barré syndrome masking an AML CNS relapse. Her symptoms completely re-
solved upon administration of a tailored treatment. This case suggests that puzzling neurological man-
ifestations in patients with a history of AML should be considered as a CNS recurrence and investigated
accordingly even in the context of normal imaging ﬁndings.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Acute myeloid leukemias (AML), stratiﬁed into different risk
categories based on cytogenetic and biomolecular analysis, re-
spond differently to therapeutic interventions implemented for
curative intent. Overall, most AML patients have complete remis-
sion but 40% commonly relapse during the ﬁrst three years [1]. It
occurs most often in the bone marrow (BM) but central nervous
system (CNS) involvement is not rare as its incidence ranges be-
tween 2% and 9% [2]. CNS leukemia can present as meningeal
leukemia, cranial nerve palsies or cerebral mesenchymal myeloid
sarcoma [3]. Peripheral neuropathy may also be a puzzling mani-
festation as it is a common complaint in clinical practice with a
very wide differential diagnosis.2. Case presentation
We report the case of an otherwise healthy 69 year-old female
patient that presented to our department for a new onset of per-
sistent disabling fatigue and 10% weight loss over two months. She
had no prior medical problems and did not complain of any other
symptoms. On clinical exam, the patient was afebrile, hypotensive
with a blood pressure of 90/50 mmHg, and tachycardic atLtd. This is an open access article u
, Hotel Dieu de France Street,
y).140 beats/min. Her initial labs showed hemoglobin 3 g/dL, white
blood cells 114.000109/L with 80% blasts, platelets of
15.000109/L, LDH of 773 U/L, SGOT of 1400 U/L and SGPT of
1416 U/L. She had increased PT and PPT with low ﬁbrinogen level
suggestive of disseminated intravascular coagulation. Qualitative
RT-PCR on BM cytology revealed the presence of CBFβ-MYH11
transcript type D (chromosome 16 inversion), and FLT3p.D835V
mutation conﬁrming an acute myelomonocytic leukemia (AML/
M4). BM cytogenetic analysis using R banding revealed a translo-
cation between chromosomes 5 and 12, 46,XX,t(5;12)(p13;p13).
Accordingly, the patient underwent 3þ7 induction chemotherapy
with cytarabine (100 mg/m2 continuous infusion days 1–7) and
idarubicin (9 mg/m2 days 1–3) although she only received a single
dose of the latter because of her abnormal liver function tests.
Analysis of her BM one month later showed complete cytologic
remission with persistence of CBFβ-MYH11 fusion transcript. The
patient received thereafter three consolidation cycles with high-
dose cytarabine. Complete molecular response was obtained three
months later.
One year after her initial diagnosis, the patient presented back
for the abrupt onset of symmetrical bilateral lower-limb weakness
and numbness. The patient did not report other symptoms or
history of trauma. Clinical examination revealed a healthy person
except for a symmetrical proximal and distal bilateral lower limbs
weakness and sensory loss with absence of deep tendon reﬂexes.
Complete blood count, LDH, and electrolytes were within normal
range. Contrast enhanced magnetic resonance imagery (MRI) of
her lumbar spine showed mild anterolisthesis of L4 on L5. Brain
MRI was normal for her age. Nerve conduction studiesnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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suggestive of Guillain–Barré syndrome. Subsequently, we per-
formed a lumbar puncture that revealed pleiocytosis with 405
blast cells according to cytology and ﬂow cytometry. Analysis of
her BM aspirate showed 3% of blasts with positive CBFβ-MYH11
fusion transcript D, and reciprocal translocation between chro-
mosomes 3 and 16 detected in 4% of examined cells,46,XX,t(3;16)
(p14;q24)[2]/46,XX[48]. We retained the diagnosis of isolated AML
CNS meningeal recurrence. Consequently, the patient received a
chemotherapy protocol of standard FLAG-IDA dosage with in-
trathecal chemotherapy of methotrexate (10 mg) plus dex-
amethasone (5 mg) alternating with cytarabine (50 mg) twice
weekly. The patient noted complete resolution of her symptoms
and her clinical exam was back to normal three weeks after in-
itiating chemotherapy. She remains alive after six months without
any complains.3. Discussion
Myelomonocytic and monocytic leukemias are the most com-
mon leukemia subtypes to affect extramedullary organs with CNS
involvement occurring in 20% [4]. Leukemia cells affect the CNS by
various mechanisms that may advocate speciﬁc treatment ap-
proaches. Blasts may inﬁltrate leptomeninges causing meningeal
leukemia, cranial nerves inducing cranial nerve palsies, or may
precipitate into a solid collection known as myeloid sarcoma [3].
Most commonly, patients with CNS leukemia are asymptomatic.
Nevertheless, a small number of patients describe increased in-
tracranial pressure manifesting with headache, stiff neck, mental
derangement, papilloedema, nausea and vomiting. Case reports
describe rare presentations of cranial nerve palsies and cauda
equine syndrome [5–7].
Literature describes multiple risk factors for the occurrence of
CNS relapse in adult patients with AML: French–American–British
classiﬁcation (FAB) M4/M5 subtypes, cytogenetic abnormality in-
version 16, male sex, high white blood cell count at diagnosis,
elevated serum lyzozyme and lactate dehydrogenase concentra-
tions [2,8,9]. Aside from her gender, our patient had the other four
mentioned risk factors. One recent paper reported a high pre-
valence of FLT3 mutations in AML patients with CNS relapse. Of
particular signiﬁcance is a recent multivariate analysis that de-
monstrated that the use of old instead of new generation ther-
apeutic induction regimens is the only factor affecting CNS relapse
[11].
In the absence of a consensus for the optimal therapy for adult
AML CNS recurrence, treatment approaches are extrapolated from
studies of paediatric AML and acute lymphoblastic leukemia (ALL).
Generally, isolated CNS leukemia relapse is considered a systemic
disease independently of the BM status and requires systemic
chemotherapy as local control is not sufﬁcient. The optimal regi-
men is guided by the clinical presentation and pathophysiology of
the CNS AML relapse. One study subdivided patients into me-
ningeal leukemia, cranial nerve palsy, and cerebral parenchymal
myeloid sarcoma and tailored their treatments accordingly [3]. The
study resulted in 70.6% CNS remission without affecting long-term
survival (overall survival 6.64 months).
Aside from case reports, only three small series report this
entity. The ﬁrst paper by Holmes et al. in 1987 describing CNS
relapse in acute myelomonocytic leukemia reports 35% CNS re-
lapse at a median of 19 months after complete remission [9].
Another study showed CNS leukemia recurrence on follow up in
2.2% of cases, remitters had a median survival of 10 months whilst
nonremitters survived two months only [10]. One last article by
Cuadron et al. in 2011 examined 458 adult patients with a diag-
nosis of non-promyelocytic AML and reported CNS involvement atﬁrst relapse in six patients of whom only two cases had isolated
CNS relapse. The overall 5-year cumulative incidence of CNS re-
lapse is 1.3% with a median of seven months (range 1–16 months)
[11].4. Conclusion
To our knowledge, this is the ﬁrst case that presents a pseudo-
Guillain–Barré syndrome uncovering a CNS leukemia recurrence.
As shown by our literature review, it deserves to be highlighted
because it underlines the possibility of a rare and atypical pre-
sentation of AML recurrence. Moreover, our case suggests that
puzzling neurological manifestations in patients with a history of
AML should be investigated for CNS AML recurrence and not
simply attributed to the neurotoxicity of chemotherapy. As in ALL,
this eventuality should be considered in AML and prompt thor-
ough investigations even in the context of normal imaging
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